Tim Wyant

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands et al. · New England Journal of Medicine · 2013 · 2.9K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

Dulce Soler, Tobias R. Chapman, Tim Wyant et al. · Journal of Pharmacology and Experimental Therapeutics · 2009 · 460 citations

Life Sciences, Immunology, Pharmacology +17

Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study

Asit Parikh, Timothy Leach, Tim Wyant et al. · Inflammatory Bowel Diseases · 2011 · 207 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10

Effect of CC Chemokine Receptor 2 CCR2 Blockade on Serum C-Reactive Protein in Individuals at Atherosclerotic Risk and With a Single Nucleotide Polymorphism of the Monocyte Chemoattractant Protein-1 Promoter Region

Jim Gilbert, Julie Lekstrom-Himes, Debra D. Donaldson et al. · The American Journal of Cardiology · 2011 · 181 citations

Life Sciences, Immunology, Molecular Biology +17

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results

Tim Wyant, Tim Leach, Serap Sankoh et al. · Gut · 2014 · 178 citations

Life Sciences, Immunology, Pharmacotherapy +17